人趋化因子CCL28小分子配体的片段药物发现

IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS SLAS Discovery Pub Date : 2023-06-01 Epub Date: 2023-02-23 DOI:10.1016/j.slasd.2023.02.004
Angela L. Zhou , Davin R. Jensen , Francis C. Peterson , Monica A. Thomas , Roman R. Schlimgen , Michael B. Dwinell , Brian C. Smith , Brian F. Volkman
{"title":"人趋化因子CCL28小分子配体的片段药物发现","authors":"Angela L. Zhou ,&nbsp;Davin R. Jensen ,&nbsp;Francis C. Peterson ,&nbsp;Monica A. Thomas ,&nbsp;Roman R. Schlimgen ,&nbsp;Michael B. Dwinell ,&nbsp;Brian C. Smith ,&nbsp;Brian F. Volkman","doi":"10.1016/j.slasd.2023.02.004","DOIUrl":null,"url":null,"abstract":"<div><p>The mucosal chemokine CCL28 is a promising target for immunotherapy drug development due to its elevated expression level in epithelial cells and critical role in creating and maintaining an immunosuppressive tumor microenvironment. Using sulfotyrosine as a probe, NMR chemical shift mapping identified a potential receptor-binding hotspot on the human CCL28 surface. CCL28 was screened against 2,678 commercially available chemical fragments by 2D NMR, yielding thirteen verified hits. Computational docking predicted that two fragments could occupy adjoining subsites within the sulfotyrosine recognition cleft. Dual NMR titrations confirmed their ability to bind CCL28 simultaneously, thereby validating an initial fragment pair for linking and merging strategies to design high-potency CCL28 inhibitors.</p></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"28 4","pages":"Pages 163-169"},"PeriodicalIF":2.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339762/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28\",\"authors\":\"Angela L. Zhou ,&nbsp;Davin R. Jensen ,&nbsp;Francis C. Peterson ,&nbsp;Monica A. Thomas ,&nbsp;Roman R. Schlimgen ,&nbsp;Michael B. Dwinell ,&nbsp;Brian C. Smith ,&nbsp;Brian F. Volkman\",\"doi\":\"10.1016/j.slasd.2023.02.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The mucosal chemokine CCL28 is a promising target for immunotherapy drug development due to its elevated expression level in epithelial cells and critical role in creating and maintaining an immunosuppressive tumor microenvironment. Using sulfotyrosine as a probe, NMR chemical shift mapping identified a potential receptor-binding hotspot on the human CCL28 surface. CCL28 was screened against 2,678 commercially available chemical fragments by 2D NMR, yielding thirteen verified hits. Computational docking predicted that two fragments could occupy adjoining subsites within the sulfotyrosine recognition cleft. Dual NMR titrations confirmed their ability to bind CCL28 simultaneously, thereby validating an initial fragment pair for linking and merging strategies to design high-potency CCL28 inhibitors.</p></div>\",\"PeriodicalId\":21764,\"journal\":{\"name\":\"SLAS Discovery\",\"volume\":\"28 4\",\"pages\":\"Pages 163-169\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339762/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SLAS Discovery\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2472555223000199\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/2/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Discovery","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2472555223000199","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

粘膜趋化因子CCL28由于其在上皮细胞中的表达水平升高以及在创建和维持免疫抑制肿瘤微环境中的关键作用,是免疫治疗药物开发的一个有前途的靶点。使用磺基酪氨酸作为探针,NMR化学位移图确定了人CCL28表面上潜在的受体结合热点。通过2D NMR针对2678个市售化学片段筛选CCL28,产生13个经验证的命中率。计算对接预测,两个片段可能占据磺基酪氨酸识别裂缝内的相邻子位点。双NMR滴定证实了它们同时结合CCL28的能力,从而验证了用于连接和合并策略的初始片段对,以设计高效CCL28抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28

The mucosal chemokine CCL28 is a promising target for immunotherapy drug development due to its elevated expression level in epithelial cells and critical role in creating and maintaining an immunosuppressive tumor microenvironment. Using sulfotyrosine as a probe, NMR chemical shift mapping identified a potential receptor-binding hotspot on the human CCL28 surface. CCL28 was screened against 2,678 commercially available chemical fragments by 2D NMR, yielding thirteen verified hits. Computational docking predicted that two fragments could occupy adjoining subsites within the sulfotyrosine recognition cleft. Dual NMR titrations confirmed their ability to bind CCL28 simultaneously, thereby validating an initial fragment pair for linking and merging strategies to design high-potency CCL28 inhibitors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
SLAS Discovery
SLAS Discovery Chemistry-Analytical Chemistry
CiteScore
7.00
自引率
3.20%
发文量
58
审稿时长
39 days
期刊介绍: Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology. SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).
期刊最新文献
High throughput, automated and fully contained cytokine release assay using primary human CD4+ T cells FRET prioritization score to choose high-quality hit equity and reduce the impact of interference by quenching and fluorescence The emerging synergy of experimental and computational approaches for therapeutic modulation of biomolecular condensates Repurposing drug screen for the identification of helicase inhibitors from viruses of pandemic concern Cleaving through complexity: Pan-serotype fluorimetric assays for the dengue virus proteases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1